Incremental Predictive Value and Representation of Transcriptomic Features for Immunotherapy Response in Advanced Urothelial Carcinoma
Han, G. Y.; Tai, H.; Wang, F.
Show abstract
Transcriptomic profiling may improve immunotherapy response prediction, but its incremental value beyond established clinical and tumor biomarkers is unclear. In 298 patients with advanced urothelial carcinoma from IMvigor210, an atezolizumab (PD-L1 inhibitor) trial, we compared knowledge-guided tumor microenvironment gene-set features with data-driven transcriptome-wide gene selection. Knowledge-guided features improved AUPRC by 0.058 beyond clinical variables alone, with smaller gains after including standard biomarkers (TMB, PD-L1; +0.011) and research-enriched biomarkers (neoantigen burden, immune phenotype; +0.016). Data-driven gene selection was unstable across folds (mean Jaccard similarity, 0.227) and, under the clinical-plus-biomarker baseline, yielded an AUPRC 0.150 lower than the knowledge-guided representation. Despite this instability, IL-6/JAK/STAT3 signaling was the most recurrent Hallmark pathway, suggesting pathway-level biological convergence. External evaluation showed a similar pattern: knowledge-guided features improved AUPRC by 0.128 over clinical variables vs. 0.019 over clinical-plus-biomarker baseline. These findings support biologically informed transcriptomic representation when molecular profiling adds value beyond established biomarkers.
Matching journals
The top 5 journals account for 50% of the predicted probability mass.
Similar papers in this journal
- Tumor-agnostic transcriptome-based classifier identifies spatial infiltration patterns of CD8+ T cells in the tumor microenvironment and predicts clinical outcome in early- and late-phase clinical trials 95%
- A Spatial Comparison of Molecular Features Associated with Resistance to Pembrolizumab in BCG Unresponsive Bladder Cancer 94%
- Conditional activation of immune-related signatures and prognostic significance: a pan-cancer analysis 93%
Similar papers in this journal
- Phase 1b dose expansion and translational analyses of olaparib in combination with the oral AKT inhibitor capivasertib in recurrent endometrial, triple negative breast, and ovarian, primary peritoneal, or fallopian tube cancer 92%
- Myeloid cell-associated resistance to PD-1/PD-L1 blockade in urothelial cancer revealed through bulk and single-cell RNA sequencing 92%
- Combinatorial benefit without synergy in recent clinical trials of immune checkpoint inhibitors 92%
Similar papers in this journal
- Predicting immunotherapy response in advanced bladder cancer: a meta-analysis of six independent cohorts 94%
- Adjuvant nivolumab, capecitabine or the combination in patients with residual triple-negative breast cancer: the OXEL randomized phase II study 94%
- Angiogenic and Immune Predictors of Neoadjuvant Axitinib Response in Renal Cell Carcinoma with Venous Tumour Thrombus 94%
Similar papers in this journal
- Genomic and transcriptomic determinants of therapy resistance and immune landscape evolution during anti-EGFR treatment in colorectal cancer 94%
- The Tumor Profiler Study: Integrated, multi-omic, functional tumor profiling for clinical decision support 93%
- AI-Driven Predictive Biomarker Discovery with Contrastive Learning to Improve Clinical Trial Outcomes 92%
Similar papers in this journal
- Development of an artificial intelligence-generated, explainable treatment recommendation system for urothelial carcinoma and renal cell carcinoma to support multidisciplinary cancer conferences 91%
- Late immune-related adverse events in long-term responders to PD-1/PD-L1 checkpoint inhibitors: a multicentre study. 90%
- Baseline tumor-infiltrating lymphocyte patterns and response to immune checkpoint inhibition in metastatic cutaneous melanoma 90%
"Similar papers" are the closest papers from that journal in the model's embedding space. They show what the match is built on, but the ranking comes mostly from a classifier over the whole training set, not from these examples alone.